BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

WuXi AppTec Reports First Quarter 2024 Financial Results: Solid Performance with Continued Growth in R&D Services

First Quarter 2024 Financial Highlights: Revenue of RMB 7,982 million, with a slight decrease of 1.8% in non-COVID-19 commercial projects, underscoring ...

April 30, 2024 | Company results

Sino Biological Completes $48M Acquisition of Canadian Firm SignalChem Biotech

Sino Biological, Inc. , a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, specializing in biological research reagents...

April 29, 2024 | News

Dizal to Present New Data on Sunvozertinib for Lung Cancer at ASCO 2024

Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases...

April 25, 2024 | News

GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Adm...

April 22, 2024 | News

Teva Validates AJOVY® Efficacy and Safety in China Phase 3 Migraine Trial

AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significanc...

April 15, 2024 | News

TransThera Sciences Presents Breakthrough Research on Tinengotinib for Advanced Solid Tumors with FGFR1-3 Alterations at AACR 2024

TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster present...

April 15, 2024 | News

BioCity Biopharma's Cancer Therapy BC2027 Gets FDA Nod for Phase 1 Trials

BioCity Biopharma announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Pha...

April 10, 2024 | News

D3 Bio Secures $62M in Series A+ Financing for Cancer Drug Development

D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its cl...

April 09, 2024 | News

Transcenta and Agilent Collaborate on Companion Diagnostic for Advanced Gastric Cancer Trial

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...

April 09, 2024 | News

Dizal's Sunvozertinib Secures FDA Breakthrough Therapy Designation for First-Line EGFR Mutated NSCLC Treatment

Dizal announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the firs...

April 08, 2024 | News

Merck Expands M Lab™ Collaboration Center in Shanghai

Additional € 14 million investment provides new opportunities for local and regional clients Adds 2,000 square meters of new collaboration space, i...

April 05, 2024 | News

TAE Life Sciences' Neutron Beam System Approved, Paving Way for BNCT Trials in China

TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the successful completion of a...

April 04, 2024 | News

RemeGen's Telitacicept Secures FDA Fast Track Status for Primary Sjögren's Syndrome Treatment

RemeGen , a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) rec...

April 03, 2024 | News

Innovent and HUTCHMED's Endometrial Cancer Therapy Receives Priority Review by China's NMPA

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

April 03, 2024 | News

Stay Connected